大腸がん ～治療ガイドライン
ガイドライン文中の文献番号から，該当する文献リストへリンクされます
文献
1） Kudo S: Endoscopic mucosal resection of flat and depressed early colorectal cancer. Endoscopy 1993; 25: 455-461
2） 井上晴洋，竹下公矢，遠藤光夫，他: 早期胃癌に対する内視鏡的粘膜切除術―透明プラスチックキャップを用いる方法（EMRC）―．Gastroenterol Endosc 1993; 35: 600-607
3） Tanaka S, Oka S, Chayama K: Colorectal endoscopic submucosal dissection（ESD）: the present status and future perspective including its differentiation from endoscopic mucosal resection（EMR）. J Gastroenterol 2008; 43: 641-651
4） Saitoh Y, Obara T, Watari J, et al: Invasion depth diagnosis of depressed type early colorectal cancers by combined use of videoendoscopy and chromoendoscopy. Gastrointest Endosc 1998; 48: 362-370
5） Watari J, Saitoh Y, Obara T, et al: Early nonpolypoid colorectal cancer: radiographic diagnosis of depth of invasion. Radiology 1997; 205: 67-74
6） Tanaka S, Kaltenbach T, Chayama K, et al: High-magnification colonoscopy. Gastrointest Endosc 2006; 64: 604-613
7） 浜本順博，平田一郎，安本真悟，他: 早期大腸癌における浸潤度の臨床診断精度―超音波内視鏡を中心に．胃と腸2004; 39: 1375-1386
8） 若村邦彦，工藤進英，竹村織江，他: 大腸腺腫・早期癌の内視鏡切除後のfollow up．胃と腸2007; 42: 1453-1457
9） 浦上尚之，五十嵐正広，千野晶子，他: 大腸SM 癌の内視鏡切除後のfollow up―サーベイランスに向けて（局所再発，転移再発）．胃と腸2007; 42: 1470-1476
10） Oka S, Tanaka S, Kanao H, et al: Mid-term prognosis after endoscopic resection for submucosal colorectal carcinoma: summary of a multicenter questionnaire survey conducted by the colorectal endoscopic resection standardization implementation working group in Japanese Society for Cancer of the Colon and Rectum. Dig Endosc 2011; 23: 190-194
11） Japanese Society for Cancer of the Colon and Rectum: Multi-institutional registry of large bowel cancer in Japan, Cases treated in 2000-2002. Vol. 29（2011）, Cases treated in 2003-2004. Vol. 30（2012）
12） Heald RJ, Husband EM, Ryall RD: The mesorectum in rectal cancer surgery―the clue to pelvic recurrence? Br J Surg 1982; 69: 613-616
13） MacFarlane JK, Ryall RD, Heald RJ: Mesorectal excision for rectal cancer. Lancet 1993; 341: 457-460
14） Enker WE, Thaler HT, Cranor ML, et al: Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995; 181: 335-346
15） Lowry AC, Simmang CL, Boulos P, et al: Consensus statement of definitions for anorectal physiology and rectal cancer. Dis Colon Rectum 2001; 44: 915-919
16） Sugihara K, Kobayashi H, Kato T, et al: Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 2006; 49: 1663-1672
17） Hida J, Yasutomi M, Maruyama T, et al: The extent of lymph node dissection for colon carcinoma: the potential impact on laparoscopic surgery. Cancer 1997; 80: 188-192
18） Ono C, Yoshinaga K, Enomoto M, et al: Discontinuous rectal cancer spread in the mesorectum and the optimal distal clearance margin in situ. Dis Colon Rectum 2002; 45: 744-749
19） Shimada Y, Takii Y, Murayama S, et al: Intramural and mesorectal distal spread detected by whole-mount sections in the determination of optimal distal resection margin in patients undergoing surgery for rectosigmoid or rectal cancer without preoperative therapy. Dis Colon Rectum 2011; 54: 1510-1520
20） Shirouzu K, Isomoto H, Kakegawa T: Distal spread of rectal cancer and optimal distal margin of resection for sphincter-preserving surgery. Cancer 1995; 76: 388-392
21） Zhao GP, Zhou ZG, Lei WZ, et al: Pathological study of distal mesorectal cancer spread to determine a proper distal resection margin. World J Gastroenterol 2005; 11: 319-322
22） 大腸癌研究会: 大腸癌取扱い規約，第8 版，東京，金原出版; 2013
23） Mentges B, Buess G, Schäfer D, et al: Local therapy of rectal tumors. Dis Colon Rectum1996; 39: 886-892
24） Maeda K, Maruta M, Sato H, et al: Outcomes of novel transanal operation for selected tumors in the rectum. J Am Coll Surg 2004; 199: 353-360
25） Santibanes E, Lassalle FB, McCormack L, et al: Simultaneous colorectal and hepatic resections for colorectal cancer: Postoperative and longterm outcomes. J Am Coll Surg 2002; 195: 196-202
26） 望月英隆: 腹膜播種を伴う大腸癌．上西紀夫，田中雅夫（編），消化器癌の外科治療，東京，中外医学社; 2001: 100-102
27） 岡 正朗，内山哲史，森近博史，他: 腹膜播種を伴う大腸癌症例の臨床病理学的検討―肝転移例との比較―．日臨外医会誌1993; 54: 2535-2539
28） 正木忠彦，武藤徹一郎，安富正幸: 大動脈周囲リンパ節の実態―第44 回大腸癌研究会アンケート調査報告．日本大腸肛門病会誌1997; 50: 318-330
29） Murata S, Moriya Y, Akasu T, et al: Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998; 83: 1086-1093
30） Kobayashi K, Kawamura M, Ishihara T: Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. J Thorac Cardiovasc Surg 1999; 118: 1090-1096
31） Portier G, Elias D, Bouche O, et al: Multicentric randomized trial of adjuvant fluorouracil and folnic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-4982
32） Mitry E, Fields AL, Bleiberg H, et al: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-4911
33） Robinson BJ, Rice TW, Strong SA, et al: Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? J Thorac Cardiovasc Surg 1999; 117: 66-76
34） 森谷冝皓，山口高史，赤須孝之，他: 骨盤内局所再発癌に対する積極的外科治療．臨外2001; 56: 759-765
35） Lambert LA, Colacchio TA, Barth RJ Jr: Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg 2000; 135: 473-479
36） Yoshidome H, Kimura F, Shimizu H, et al: Interval period tumor progression: does delayed hepatectomy detect occult metastases in synchronous colorectal liver metastases? J Gastrointest Surg 2008; 12: 1391-1398
37） Adam R: Developing strategies for liver metastases from colorectal cancer. Semin Oncol 2007; 34（2 Suppl 1）: S7-11
38） Lam VW, Spiro C, Laurence JM, et al: A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 2012; 19: 1292-1301
39） 亀岡信悟，小川真平: 治療方針確定のための検査計画．杉原健一（編），再発大腸癌治療ガイドブック，東京，南江堂; 2003: 77-83
40） Hahnloser D, Nelson H, Gunderson LL, et al: Curative potential of multimodality therapy for locally recurrent rectal cancer. Ann Surg 2003; 237: 502-508
41） Tschmelitsch J, Kronberger P, Glaser K, et al: Survival after surgical treatment of recurrent carcinoma of the rectum. J Am Coll Surg 1994; 179: 54-58
42） Tanis PJ, Doeksen A, van Lanschot JJ: Intentionally curative treatment of locally recurrent rectal cancer: a systematic review. Can J Surg 2013; 56: 135-144
43） Martin LW, Warren RS: Current management of colorectal liver metastases. Surg Oncol Clin N Am 2000; 9: 853-876
44） Penna C, Nordlinger B: Colorectal metastasis（liver and lung）. Surg Clin North Am 2002; 82: 1075-1090
45） Abdalla EK, Vauthey JN, Ellis LM, et al: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-825; discussion 825-827
46） Kato T, Yasui K, Hirai T, et al: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy. Dis Colon Rectum 2003; 46（Suppl）: S22-S31
47） Niekel MC, Bipat S, Stoker J: Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010; 257: 674-684
48） Fortner JG, Silva JS, Golbey RB, et al: Multivariate analysis of hepatic metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg 1984; 199: 306-316
49） Hughes KS, Simon R, Songhorabodi S, et al: Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of pattern of recurrence. Surgery 1986; 100: 278-284
50） Ekberg H, Tranberg KG, Andersson R, et al: Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 1987; 11: 541-547
51） Nordinger B, Jaeck D, Guiguet M, et al: Surgical resection of hepatic metastases. Multicentric retrospective study by the French Association of Surgery. In: Nordinger B, Jaeck D, editors, Treatment of hepatic metastases of colorectal cancer. Paris Springer-Verlag 1992: 129-146
52） Cady B, Jenkins RL, Steele Jr GD, et al: Surgical margin in hepatic resection for colorectal metastases: a critical and improvable determinant of outcome. Ann Surg 1998; 227: 566-571
53） Yamamoto J, Sugihara K, Kosuge T, et al: Pathologic support for limited hepatectomy in the treatment of liver metastases from colorectal cancer. Ann Surg 1995; 221: 74-78
54） Elias D, Cavalcanti A, Sabourin JC, et al: Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol 1998; 69: 88-93
55） Fong Y, Cohen AM, Fortner JG, et al: Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-946
56） Kokudo N, Miki Y, Sugai S, et al: Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 2002; 137: 833-840
57） Bismuth H, Castaing D, Traynor O: Surgery for synchronous hepatic metastases of colorectal cancer. Scand J Gastroenterol Suppl 1988; 149: 144-149
58） Scheele J: Hepatectomy for liver metastases. Br J Surg 1993; 80: 274-276
59） Rodgers MS, McCall JL: Surgery for colorectal liver metastases with hepatic lymph-node involvement: a systematic review. Br J Surg 2000; 87: 1142-1155
60） Beckurts KT, Hölscher AH, Thorban ST, et al: Significance of lymph node imvolvement at the hepatic hilum in the resection of colorectal liver metastases. Br J Surg 1997; 84: 1081-1084
61） Nakamura S, Suzuki S, Konno H: Resection of hepatic metastases of colorectal carcinoma: 20years’ experience. J Hepatobiliary Pancreat Surg 1999; 6: 16-22
62） Regnard JF, Grunenwald D, Spaggiari L, et al: Surgical treatment for hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998; 66: 214-218
63） Carpizo DR, Are C, Jarnagin W, et al: Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol 2009; 16: 2138-2146
64） Nordlinger B, Vaillant JC, Guiguet M, et al: Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 1994; 12: 1491-1496
65） Yamamoto J, Kosuge T, Shimada K, et al: Repeat liver resection for recurrent colorectal liver metastases. Am J Surg 1999; 178: 275-281
66） Petrowsky H, Gonen M, Jarnagin W, et al: Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002; 235: 863-871
67） Suzuki S, Sakaguchi T, Yokoi Y, et al: Impact of repeat hepatectomy on recurrent colorectal liver metastases. Surgery 2001; 129: 421-428
68） Nagakura S, Shirai Y, Suda T, et al: Multiple repeat resections of intra- and extrahepatic recurrences in patients undergoing initial hepatectomy for colorectal carcinoma metastases. World J Surg 2002; 26: 141-147
69） Tanaka K, Shimada H, Ohta M, et al: Procedures of choice for resection of primary and recurrent liver metastases from colorectal cancer. World J Surg 2004; 28: 482-487
70） Thelen A, Jonas S, Benckert C, et al: Repeat liver resection for recurrent liver metastases from colorectal cancer. Eur J Surg Oncol 2007; 33: 324-328
71） Pessaux P, Lermite E, Brehant O, et al: Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol 2006; 93: 1-7
72） Ishiguro S, Akasu T, Fujimoto Y, et al: Second hepatectomy for recurrent colorectal liver metastasis: analysis of preoperative prognostic factors. Ann Surg Oncol 2006; 13: 1579-1587
73） 別府 透，松田貞士，前田健晴，他: 転移性肝癌へのマイクロ波凝固療法の応用．外科治療2000; 83: 237-242
74） Shibata T, Niinobu T, Ogata N, et al: Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 2000; 89: 276-284
75） Park IJ, Kim HC, Yu CS, et al: Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. Ann Surg Oncol 2008; 15: 227-232
76） Wong SL, Mangu PB, Choti MA, et al: American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010; 28: 493-508
77） Tree AC, Khoo VS, Eeles RA, et al: Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013; 14: e28-37
78） Goya T, Miyazawa N, Kondo H, et al: Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. Cancer 1989; 64: 1418-1421
79） McCormack PM, Burt ME, Bains MS, et al: Lung resection of colorectal metastases. 10-year results. Arch Surg 1992; 127: 1403-1406
80） Ike H, Shimada H, Ohki S, et al: Results of aggressive resection of lung metastases from colorectal carcinoma detected by intensive follow-up. Dis Colon Rectum 2002; 45: 468-475
81） Okumura S, Kondo H, Tsuboi M, et al: Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 1996; 112: 867-874
82） McAfee MK, Allen MS, Trastek VF, et al: Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992; 53: 780-785
83） 緒方 裕，的野敬子，林 明宏，他: 大腸癌肺転移に対する肺切除の遠隔成績．日臨外会誌 2001; 62: 2110-2115
84） 丸田智章，須田武保，畠山勝義，他: 大腸癌肺転移に対する肺切除の検討．日消外会誌2002; 35: 1377-1383
85） Saito Y, Omiya H, Kohno K, et al: Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002; 124: 1007-1013
86） 金光幸秀，加藤知行，平井 孝: 大腸癌肺転移に対する治療の現況―第55 回大腸癌研究会アンケート結果―．日本大腸肛門病会誌2004; 57: 121-131
87） 斎藤 裕，高田宗尚，矢鋪憲功，他: 大腸癌肺転移の手術成績からみた手術適応．北陸外科学会雑誌2005; 24: 5-8
88） 東山聖彦，高見康二，檜垣直純，他: 大腸癌肺転移に対する外科治療―手術適応，工夫と成績について―．臨床消化器内科2005; 20: 199-206
89） Koga R, Yamamoto J, Saiura A, et al: Surgical resection of pulmonary metastases from colorectal cancer: four favourable prognostic factors. Jpn J Clin Oncol 2006; 36: 643-648
90） Iizasa T, Suzuki M, Yoshida S, et al: Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 2006; 82: 254-260
91） Watanabe K, Nagai K, Kobayashi A, et al: Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg 2009; 96: 1058-1065
92） Hirosawa T, Itabashi M, Ohnuki T, et al; Japanese Society for Cancer of the Colon and Rectum（JSCCR）Study Group for Pulmonary Metastases from Colorectal Cancer: Prognostic factors in patients undergoing complete resection of pulmonary metastases of colorectal cancer: a multi-institutional cumulative follow-up study. Surg Today 2013; 43: 494-499
93） Miller G, Biernacki P, Kemeny NE, et al: Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 2007; 205: 231-238
94） Kandioler D, Krömer E, Tüchler H, et al: Long-term results after repeated surgical removal of pulmonary metastases. Ann Thorac Surg 1998; 65: 909-912
95） Kanzaki R, Higashiyama M, Oda K, et al: Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma. Am J Surg 2011; 202: 419-426
96） Patchell RA, Tibbs PA, Walsh JW, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494-500
97） Go PH, Klaassen Z, Meadows MC, et al: Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer 2011; 117: 3630-3640
98） Wronski M, Arbit E: Resection of brain metastases from colorectal carcinoma in 73 patients. Cancer 1999; 85: 1677-1685
99） D ’Andrea G, Isidori A, Caroli E, et al: Single cerebral metastasis from colorectal adenocarcinoma. Neurosurg Rev 2004; 27: 55-57
100） Farnell GF, Buckner JC, Cascino T: Brain metastases from colorectal carcinoma. Cancer 1996; 78: 711-716
101） Jung M, Ahn JB, Chang JH, et al: Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol 2011; 101: 49-55
102） Aprile G, Zanon E, Tuniz F, et al: Neurosurgical management and postoperative wholebrain radiotherapy for colorectal cancer patients with symptomatic brain metastases. J Cancer Res Clin Oncol 2009; 135: 451-457
103） Noura S, Ohue M, Shingai T, et al: Brain metastasis from colorectal cancer: prognostic factors and survival. J Surg Oncol 2012; 106: 144-148
104） Borgelt B, Gelber R, Kramer S, et al: The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980; 6: 1-9
105） Kurtz JM, Gelber R, Brady LW, et al: The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981; 7: 891-895
106） Flickinger JC, Kondziolka D, Lunsford LD, et al: A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 1994; 28: 797-802
107） Gasper L, ScottC, Rotman M, et al: Recursive partitioning analysis（RPA）of prognostic factors in three Radiation Therapy Oncology Group（RTOG）brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745-751
108） van Gijn W, Marijnen CA, Nagtegaal ID, et al: Dutch Colorectal Cancer Group: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12: 575-582
109） Sperduto PW, Kased N, Roberge D, et al: Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30: 419-425
110） Andrews DW, Scott CB, Sperduto PW, et al: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase Ⅲ results of the RTOG 9508 randomised trial. Lancet 2004; 363: 1665-1672
111） Aoyama H, Shirato H, Tago M, et al: Stereotactic radiosurgery plus whole-brain radiotherapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295: 2483-2491
112） National Institute of Health Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444-1450
113） Benson AB Ⅲ, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage Ⅱ colon cancer. J Clin Oncol 2004; 22: 3408-3419
114） Schmoll HJ, Van Cutsem E, Stein A, et al: ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-2516
115） Des Guetz G, Nicolas P, Perret GY, et al: Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 2010; 46: 1049-1055
116） Biagi JJ, Raphael MJ, Mackillop WJ, et al: Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and metaanalysis. JAMA 2011; 305: 2335-2342
117） Lembersky, BC, Wieand, HS, Petrelli, NJ, et al: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage Ⅱ and Ⅲ carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24: 2059-2064
118） Twelves C, Wong A, Nowacki MP, et al: Capecitabine as adjuvant treatment for stage Ⅲ colon cancer. N Engl J Med 2005; 352: 2696-2704
119） André T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer（MOSAIC） Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351
120） Kuebler JP, Wieand HS, O’Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage Ⅱ and Ⅲ colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204
121） André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage Ⅱ or Ⅲ colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116
122） Yothers G, O’Connell MJ, Allegra CJ, et al: Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29: 3768-3774
123） Haller DG, Tabernero J, Maroun J, et al: Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage Ⅲ colon cancer. J Clin Oncol 2011; 29: 1465-1471
124） Japanese Society for Cancer of the Colon and Rectum: Multi-Institutional Registry of Large Bowel Cancer in Japan. Vol. 30 Cases treated in 2003-2004. Published in October 2012
125） Saltz LB, Niedzwiecki D, Hollis D, et al: Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage Ⅲ colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25: 3456-3461
126） Ychou M, Raoul JL, Douillard JY, et al: A phase Ⅲ randomised trial of LV5FU2＋irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer（FNCLCC Accord02/FFCD9802）. Ann Oncol 2009; 20: 674-680
127） Van Cutsem E, Labianca R, Bodoky G, et al: Randomized phase Ⅲ trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage Ⅲ colon cancer: PETACC-3. J Clin Oncol 2009; 27: 3117-3125
128） Allegra CJ, Yothers G, O’Connell MJ, et al: Phase Ⅲ trial assessing bevacizumab in stages Ⅱ and Ⅲ carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011; 29: 11-16
129） de Gramont A, Van Cutsem E, Schmoll HJ, et al: Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer（AVANT）: a phase 3 randomised controlled trial. Lancet Oncol 2012; 13: 1225-1233
130） Alberts SR, Sargent DJ, Nair S, et al: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage Ⅲ colon cancer: a randomized trial. JAMA 2012; 307: 1383-1393
131） Taieb J, Tabernero J, Mini E, et al: Adjuvant FOLFOX4＋/－cetuximab in KRAS wildtype patients with resected stage Ⅲ colon cancer results from the PETACC8 intergroup trial. Ann Oncol 2012; 23: iv5-iv18
132） Kato T, Ohashi Y, Nakazato H, et al: Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbecks Arch Surg 2002; 386: 575-581
133） Akasu T, Moriya Y, Ohashi Y, et al: Adjuvant chemotherapy with uracil-tegafur for pathological stage Ⅲ rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 2006; 36: 237-244
134） Sakamoto J, Hamada C, Yoshida S, et al: An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur（UFT）in patients with curatively resected rectal cancer. Br J Cancer 2007; 96: 1170-1177
135） Scheithauer W, Rosen H, Kornek GV, et al: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752-755
136） Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Br Med J 2000; 321: 531-535
137） Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418
138） Haller DG, Catalano PJ, Macdonald JS, et al: Phase Ⅲ study of fluorouracil, leucovorin, and levamisole in high-risk stage Ⅱ and Ⅲ colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23: 8671-8678
139） de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947
140） Goldberg R, Sargent D, Morton R, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30
141） Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase Ⅲ study. J Clin Oncol 2008; 26: 2013-2019
142） Cassidy J, Clarke S, Díaz-Rubio E, et al: Randomized phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012
143） Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A Randomized GERCOR Study. J Clin Oncol 2004; 22: 229-237
144） Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047
145） Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786
146） Fuchs CS, Marshall J, Barrueco J, et al: Randomized, controlled trial of irinotecan plus infusional, bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008; 26: 689-690
147） Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671
148） Douillard JY, Siena S, Cassidy J, et al: Randomized, phase Ⅲ trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin（FOLFOX4）versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705
149） Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417
150） Köhne CH, Hofheinz R, Mineur L, et al: First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 2012; 138: 65-72
151） Falcone A, Ricci S, Brunetti I, et al: Gruppo Oncologico Nord Ovest: Phase Ⅲ trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan（FOLFOXIRI）compared with infusional fluorouracil, leucovorin, and irinotecan（FOLFIRI）as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676
152） Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5: 1559-1565
153） de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-815
154） Hurwitz H, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508
155） Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase Ⅱ, randomized trial comparing Bevacizumab plus fluorouracil（FU）/leucovorin（LV）with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65
156） Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase Ⅲ study. J Clin Oncol 2001; 19: 2282-2292
157） Van Cutsem E, Twelves C, Cassidy J, et al: Xeloda Colorectal Cancer Study Group: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase Ⅲ study. J Clin Oncol 2001; 19: 4097-4106
158） Tebbutt NC, Wilson K, Gebski VJ, et al: Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase Ⅲ MAX Study. J Clin Oncol 2010; 28: 3191-3198
159） Shirao K, Hoff PM, Ohtsu A, et al: Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur（UFT）plus oral leucovorin（LV）regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 2004; 22: 3466-3474
160） Douillard JY, Hoff PM, Skillings JR, et al: Multicenter phase Ⅲ study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3605-3616
161） Carmichael J, Popiela T, Radstone D, et al: Randomized comparative study of tegafur/ uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3617-3627
162） Bennouna J, Sastre J, Arnold D, et al: ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer（ML18147）: a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37
163） Muro K, Boku N, Shimada Y, et al: Irinotecan plus S-1（IRIS）versus fluorouracil and folinic acid plus irinotecan（FOLFIRI）as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study（FIRIS study）. Lancet Oncol 2010; 11: 853-860
164） Sobrero AF, Maurel J, Fehrenbacher L, et al: EPIC: phase Ⅲ trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-2319
165） Peeters M, Price TJ, Hotko YS, et al: Randomized phase Ⅲ study of panitumumab（pmab）with FOLFIRI vs FOLFIRI alone as second-line treatment（tx）in patients（pts）with metastatic colorectal cancer（mCRC）: Patient-reported outcomes（PRO）. 2010 ASCO Gastrointestinal Cancers Symposium, 2010（. Abstr 282）
166） Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase Ⅲ trial. J Clin Oncol 2003; 21: 2059-2069
167） Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin（FOLFOX4）for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544
168） Rothenberg ML, Cox JV, Butts C, et al: Capecitabine plus oxaliplatin（XELOX）versus 5-fluorouracil/folinic acid plus oxaliplatin（FOLFOX-4）as second-line therapy in metastatic colorectal cancer: a randomized phase Ⅲ noninferiority study. Ann Oncol 2008; 19: 1720-1726
169） Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345
170） Jonker DJ, O’Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048
171） Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765
172） Van Cutsem E, Peeters M, Siena S, et al: Open-label phase Ⅲ trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664
173） Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634
174） Grothey A, Van Cutsem E, Sobrero A, et al: CORRECT Study Group: Regorafenib monotherapy for previously treated metastatic colorectal cancer（CORRECT）: an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-312
175） Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214
176） Koopman M, Antonini NF, Douma J, et al: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer（CAIRO）: a phase Ⅲ randomised controlled trial. Lancet 2007; 370: 135-142
177） Seymour MT, Maughan TS, Ledermann JA, et al: FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer（MRC FOCUS）: a randomised controlled trial. Lancet 2007; 370: 143-152
178） Cunningham D, Sirohi B, Pluzanska A, et al: Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 244-250
179） Punt CJ, Tol J, Rodenburg CJ, et al: Randomized phase Ⅲ study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer（ACC）, the CAIRO2 study of the Dutch Colorectal Cancer Group（DCCG）. Proc Am Soc Clin Oncol 2008; 26:（ Abstr LBA4011）
180） Hecht JR, Mitchell E, Chidiac T, et al: An updated analysis of safety and efficacy of oxaliplatin（Ox）/Bevacizumab（bev）＋ / －panitumumab（pmab）for first-line treatment（tx）of metastatic colorectal cancer（mCRC）from a randomized, controlled trial（PACCCE）. Gastrointestinal Cancers Symposium 2008;（ Abstr 273）
181） Meta-Analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252-258
182） Skibber JM, Hoff PM, Minsky BD, et al: Cancer of the Rectum. In: Devita VT, Hellman S, Rosenberg SA（eds）. Cancer: Principles and Practice of Oncology（6th ed）. Philadelphia, Lippincott, Williams and Wilkins 2001; 1271-1318
183） Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: 980-987
184） Camma C, Giunta M, Fiorica F, et al: Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. J Am Med Assoc 2000; 284: 1008-1015
185） Colorectal Cancer Collaborative Group: Adjuvant radiotherapy for rectal cancer: a systematic overview of 22 randomised trials involving 8507 patients. Lancet 2001; 358: 1291-1304
186） Kapiteijn E, Marijnen CA, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-646
187） Peeters KC, Marijnen CA, Nagtegaal ID, et al; Dutch Colorectal Cancer Group: The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246: 693-701
188） Marijnen CA, van de Velde CJ, Putter H, et al: Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005; 23: 1847-1858
189） Peeters KC, van de Velde CJ, Leer JW, et al: Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients―a Dutch colorectal cancer group study. J Clin Oncol 2005; 23: 6199-6206
190） Francois Y, Nemoz CJ, Baulieux J, et al: Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing sur gery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 1999; 17: 2396-2402
191） Bosset JF, Collette L, Calais G, et al: EORTC Radiotherapy Group Trial 22921: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123
192） Gerard JP, Conroy T, Bonnetain F, et al: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625
193） Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al: Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215-1223
194） Ngan SY, Burmeister B, Fisher RJ, et al: Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30: 3827-3833
195） Sauer R, Becker H, Hohenberger W, et al; German Rectal Cancer Study Group: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740
196） Hofheinz RD, Wenz F, Post S, et al: Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012; 13: 579-588
197） Roh MS, Yothers GA, O’Connell MJ, et al: The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol（Meeting Abstracts）2011; 29: 3503
198） Aschele C, Cionini L, Lonardi S, et al: Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase Ⅲ trial. J Clin Oncol 2011; 29: 2773-2780
199） Gérard JP, Azria D, Gourgou-Bourgade S, et al: Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase Ⅲ trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28: 1638-1644
200） Gérard JP, Azria D, Gourgou-Bourgade S, et al: Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012; 30: 4558-4565
201） Rödel C, Liersch T, Becker H, et al: German Rectal Cancer Study Group: Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13: 679-687
202） Wolmark N, Wieand HS, Hyams DM, et al: Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project protocol R-02. J Natl Cancer Inst 2000; 92: 388-396
203） Gervaz PA, Wexner SD, Pemberton JH: Pelvic radiation and anorectal function: introducing the concept of sphincter-preserving radiation therapy. J Am Coll Surg 2002; 195: 387-394
204） Temple LK, Wong WD, Minsky B: The impact of radiation on functional outcomes in patients with rectal cancer and sphincter preservation. Semin Radiat Oncol 2003; 13: 469-477
205） Garofalo M, Moughan J, Hong T, et al: RTOG 0822: A Phase Ⅱ Study of Preoperative （PREOP）Chemoradiotherapy（CRT）Utilizing IMRT in Combination with Capecitabine（C）and Oxaliplatin（O）for Patients with Locally Advanced Rectal Cancer. Proceedings of the American Society for Radiation Oncology 53rd Annual Meeting, ASTRO’s 53rd Annual Metting 2011; 81: S3-S4
206） O ’Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502-507
207） Smalley SR, Benedetti JK, Williamson SK, et al: Phase Ⅲ trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006; 24: 3542-3547
208） Nakfoor BM, Willett CG, Shellito PC, et al: The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer. Ann Surg 1998; 228: 194-200
209） Strassmann G, Walter S, Kolotas C, et al: Reconstruction and navigation system for intraoperative brachytherapy using the flab technique for colorectal tumor bed irradiation. Int J Radiat Oncol Biol Phys 2000; 47: 1323-1329
210） Wong CS, Cummings BJ, Brierley JD, et al: Treatment of locally recurrent rectal carcinoma―results and prognostic factors. Int J Radiat Oncol Biol Phys 1998; 40: 427-435
211） Lingareddy V, Ahmad NR, Mohiuddin M: Palliative reirradiation for recurrent rectal cancer. Int J Radiat Oncol Biol Phys 1997; 38: 785-790
212） Bates T: A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys 1992; 23: 217-221
213） Nielsen OS, Munro AJ, Tannock IF: Bone metastases: pathophysiology and management policy. J Clin Oncol 1991; 9: 509-524
214） Wu JS, Wong R, Johnston M, et al; Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group: Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003; 55: 594-605
215） Chow E, Harris K, Fan G, et al: Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007; 25: 1423-1436
216） Nishio M, Sano M, Tamaki Y, et al:［ A multicenter study to determine the efficacy and safety of strontium（89Sr）chloride for palliation of painful bony metastases in cancer patients］. ［Article in Japanese］. Nihon Igaku Hoshasen Gakkai Zasshi 2005; 65: 399-410
217） Paes FM, Serafini AN: Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 2010; 40: 89-104
218） Cancer pain relief and palliative care: Report of a WHO expert committee. WHO Technical Report Series 804. WHO, Geneva, 1990, 21-22
219） 日本緩和医療学会緩和医療ガイドライン作成委員会編: がん疼痛の薬物療法に関するガイドライン2010 年版，金原出版，東京，2010
220） Foley KM: The treatment of cancer pain. N Engl J Med 1985; 313: 84-95
221） Suzuki K, Gunderson LL, Devine RM, et al: Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer. Cancer 1995; 75: 939-952
222） Nymann T, Jess P, Christiansen J: Rate and treatment of pelvic recurrence after abdominoperineal resection and low anterior resection for rectal cancer. Dis Colon Rectum 1995; 38: 799-802
223） Tong D, Gillick L, Hendrickson FR: The palliation of symptomatic osseous metastases. Final results of the study by the radiation therapy oncology group. Cancer 1982; 50: 893-899
224） Helyer LK, Law CH, Butler M, et al: Surgery as a bridge to palliative chemotherapy in patients with malignant bowel obstruction from colorectal cancer. Ann Surg Oncol 2007; 14: 1264-1271
225） 中田 健，冨田尚裕，岡村 修，他: 切除不能進行癌・再発癌に対する緩和的人工肛門造設術の検討．外科治療2007; 96: 101-105
226） Law WL, Choi HK, Lee YM, et al: Palliation for advanced malignant colorectal obstruction by self-expanding metallic stents; prospective evaluation of outcomes. Dis Colon Rectum 2004; 47, 39-43
227） Khot UP, Lang AW, Murali K, et al: Systemic review of the efficacy and safety of colorectal stents. Br J Surg 2002; 89: 1096-1102
228） Baines M, Oliver DJ, Carter RL, et al: Medical management of intestinal obstruction in patients with advanced malignant disease. A clinical and pathological study. Lancet 2, 990-993, 1985
229） Ripamonti C, Twycross R, Baines M, et al: Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 2001; 9: 223-233
230） Maguire P, Walsh S, Jeacock J, et al: Physical and psychological needs of patients dying from colo-rectal cancer. Palliative Medicine 1999; 13: 45-50
231） Temel JS, Greer JA, Muzikansky A, et al: Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742
232） Sprangers MA, te Verde A, Aaronson NK: The construction and testing of the EORTC Colorectal Cancer-specific Quality of Life Questionnaire Module（QLQ-CR38）. Eur J Cancer 1999; 35: 238-247
233） Uki J, Mendoza T, Charles MS, et al: A brief cancer pain assessment tool in Japanese: The utility of the Japanese Brief Pain Inventory-BPI-J. J Pain Symptom Manage 1998; 16: 364-373
234） Renehan AG, Egger M, Saunders MP, et al: Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trial. Br Med J 2002; 324: 813-816.
235） Figueredo A, Rumble RB, Maroun J, et al: Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer 2003; 6: 26
236） Renehan AG, Egger M, Saunders MP, et al: Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis. Br J Cancer 2005; 92: 430-433
237） Jeffery M, Hickey BE, Hider PN: Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007; 24: CD002200
238） Tjandra JJ, Chan MK: Follow-up after curative resection of colorectal cancer: a metaanalysis. Dis Colon Rectum 2007; 50: 1783-1799
239） Bruinvels D, Stiggelbout A, Kievit J, et al: Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994; 219: 174-182
240） Fleischer D, Goldberg S, Browning T, et al: Detection and surveillance of colorectal cancer. JAMA 1989; 261: 580-585
241） Mazilu L, Ciufu N, Gălan M, et al: Postherapeutic follow-up of colorectal cancer patients treated with curative intent. Chirurgia（Bucur）2012; 107: 55-58
242） Desch CE, Benson AB 3rd, Somerfield MR, et al: Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 2005; 23: 8512-8519
243） National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology-colon cancer（version 3. 2013）. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf: accessed April 7, 2013
244） 渡辺 正，豊田美知子，伊藤勝基，他: 直腸癌局所再発診断における経時的骨盤部CT 撮影の意義．日本大腸肛門病会誌1989; 42: 1031-1038
245） Ramirez JM, Mortensen NJM, Takeuchi N, et al: Endoluminal ultrasonography in the follow-up of patients with rectal cancer. Br J Surg 1994; 81: 692-694
246） Löhnert MSS, Doniec JM, Henne-Bruns D: Effectiveness of endoluminal sonography in the identification of occult local rectal cancer recurrences. Dis Colon Rectum 2000; 43: 483-491
247） Moore HG, Akhurst T, Larson SM, et al: A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg 2003; 197: 22-28
248） Flanagan FL, Dehdashti F, Ogunbiyi OA, et al: Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998; 227: 319-323
249） Winawer S, Fletcher R, Rex D, et al: Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003; 124: 544-560
250） Rex DK, Kahi CJ, Levin B, et al; American Cancer Society; US Multi-Society Task Force on Colorectal Cancer: Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2006; 130: 1865-1871
251） Tsikitis VL, Malireddy K, Green EA, et al: Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol 2009; 27: 3671-3676
252） Metcalfe MS, Mullin EJ, Maddern GJ: Choice of surveillance after hepatectomy for colorectal metastases. Arch Surg 2004; 139: 749-754
253） Green RJ, Metlay JP, Propert K, et al: Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 2002; 136: 261-269
254） 石黒めぐみ，望月英隆，杉原健一，他: 大腸癌に合併する多発癌・重複がんに関するフォローアップについて．日本大腸肛門病会誌2006; 59: 863-868
255） Berman J, Cheung R, Weiberg D: Surveillance after colorectal cancer resection. Lancet 2000; 355: 395-399
256） 大腸癌研究会編: 遺伝性大腸癌診療ガイドライン2012 年版，金原出版，東京，2012
257） Ueno H, Mochizuki H, Hashiguchi Y, et al: Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004; 127: 385-394
258） Kitajima K, Fujimori T, Fujii S, et al: Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol 2004; 39: 534-543
259） 武田 純，長廻 紘，奥山 隆，他: 5．大腸sm 癌の取り扱い．b．内視鏡治療後の追加手術が必要な条件．武藤徹一郎（監），渡辺英伸，杉原健一，多田正大（編），大腸疾患NOW 2004，日本メディカルセンター，東京，2004: 60-69
260） Tanaka S, Haruma K, Oh-e H, et al: Conditions of curability after endoscopic resection for colorectal carcinoma with submucosally massive invasion. Oncol Rep 2000; 7: 783-788
261） 大腸癌研究会編: 大腸癌取扱い規約，第2 版，金原出版，東京，1980
262） 大腸癌研究会編: 大腸癌取扱い規約，第5 版，金原出版，東京，1994
263） 大腸癌研究会編: 大腸癌治療ガイドライン―医師用2005 年版，金原出版，東京，2005
264） Matsuda T, Fukuzawa M, Uraoka T, et al: Risk of lymph node metastasis in patients with pedunculated type early invasive colorectal cancer: a retrospective multicenter study. Cancer Sci 2011; 102: 1693-1697
265） Ikematsu H, Yoda Y, Matsuda T, et al: Long-term outcomes after resection for submucosal invasive colorectal cancers. Gastroenterology 2013; 144: 551-559
266） Moss A, Bourke MJ, Metz AJ: A randomized, double-blind trial of succinylated gelatin submucosal injection for endoscopic resection of large sessile polyps of the colon. Am J Gastroenterol 2010; 105: 2375-2382
267） Tanaka S, Terasaki M, Hayashi N, et al: Warning for unprincipled colorectal endoscopic submucosal dissection: accurate diagnosis and reasonable treatment strategy. Dig Endosc 2013; 25: 107-116
268） Uraoka T, Saito Y, Matsuda T, et al: Endoscopic indications for endoscopic mucosal resection of laterally spreading tumours in the colorectum. Gut 2006; 55: 1592-1597
269） Tanaka S, Haruma K, Oka S, et al: Clinicopathologic features and endoscopic treatment of superficially spreading colorectal neoplasms larger than 20 mm. Gastrointest Endosc 2001; 54: 62-66
270） Saito Y, Fukuzawa M, Matsuda T, et al: Clinical outcome of endoscopic submucosal dissection versus endoscopic mucosal resection of large colorectal tumors as determined by curative resection. Surg Endosc 2010; 24: 343-352
271） 今井 環: 人体癌腫発育状況の形態学的考察．福岡医誌1954; 45: 72-102
272） 河内 洋，小池盛雄．大腸癌における簇出診断の意義（2）大腸癌研究会簇出検討プロジェクトの結果．武藤徹一郎（監），杉原健一，多田正大，藤盛孝博，五十嵐正広（編），大腸疾患NOW 2007，日本メディカルセンター，東京，2007: 87-92
273） Yamamoto H: Endoscopic submucosal dissection of early cancers and large flat adenomas. Clin Gastroenterol Hepatol 2005; 3: S74-76
274） Fujishiro M, Yahagi N, Nakamura M, et al: Successful outcomes of a novel endoscopic treatment for GI tumors: endoscopic submucosal dissection with a mixture of high-molecular-weight hyaluronic acid, glycerin, and sugar. Gastrointest Endosc 2006; 63: 243-249
275） Saito Y, Uraoka T, Matsuda T, et al: Endoscopic treatment of large superficial colorectal tumors: a case series of 200 endoscopic submucosal dissections（with video）. Gastrointest Endosc 2007; 66: 966-973
276） Toyonaga T, Man-i M, Fujita T, et al: Retrospective study of technical aspects and complications of endoscopic submucosal dissection for laterally spreading tumors of the colorectum. Endoscopy 2010; 42: 714-722
277） Tanaka S, Tamegai Y, Tsuda S, et al: Multicenter questionnaire survey on the current situation of colorectal endoscopic submucosal dissection in Japan. Dig Endosc 2010; 22: S2-8
278） Saito Y, Uraoka T, Yamaguchi Y, et al: A prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections（with video）. Gastrointest Endosc 2010; 72: 1217-1225
279） Nakajima T, Saito Y, Tanaka S, et al. Current status of endoscopic resection strategy for large, early colorectal neoplasia in Japan. Surg Endosc 2013; 27: 3262-3270
280） Hirasaki S, Kozu T, Yamamoto H, et al: Usefulness and safety of 0.4％ sodium hyaluronate solution as a submucosal fluid“cushion”for endoscopic resection of colorectal mucosal neoplasms: a prospective multi-center open-label trial. BMC Gastroenterol 2009; 9: 1
281） Saito Y, Uraoka T, Matsuda T, et al: A pilot study to assess the safety and efficacy of carbon dioxide insufflation during colorectal endoscopic submucosal dissection with the patient under conscious sedation. Gastrointest Endosc 2007; 65: 537-542
282） Lacy AM, Garcia-Valdecasas JC, Delgado S, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 2002; 359: 2224-2229
283） Weeks JC, Nelson H, Gelber S, et al; Clinical Outcomes of Surgical Therapy（COST）Study Group: Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA 2002; 287: 321-328
284） Clinical Outcomes of Surgical Therapy Study Group: A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004; 350: 2050-2059
285） Veldkamp R, Kuhry E, Hop WC, et al; Colon Cancer Laparoscopic or Open Resection Study Group: Laparoscopic surgery versus open surgery for colon cancer; short-term outcomes of a randomised trial. Lancet Oncol 2005; 6: 477-484
286） Leung KL, Kwok SP, Lam SC, et al: Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial. Lancet 2004; 363: 1187-1192
287） Schwenk W, Haase O, Neudecker J, et al: Short term benefits for laparoscopic colorectal resection. Cochrane Database Syst Rev 2005; 20: CD003145. Review
288） Guillou PJ, Quirke P, Thorpe H, et al; MRC CLASICC trial group: Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer（MRC CLASICC trial）: multicentre, randomised controlled trial. Lancet 2005; 365: 1718-1726
289） Jayne DG, Guillou PJ, Thorpe H, et al: Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007; 25: 3061-3068
290） Colon Cancer Laparoscopic or Open Resection Study Group, Buunen M, Veldkamp R, Hop WC, et al: Survival after laparoscopic surgery versus open surgery for colon cancer: longterm outcome of a randomised clinical trial. Lancet Oncol 2009; 10: 44-52
291） Kuhry E, Schwenk W, Gaupset R, et al: Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev 2008;（ 2）: CD003432
292） Green BL, Marshall HC, Collinson F, et al: Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. Br J Surg 2013; 100: 75-82
293） Kitano S, Inomata M, Sato A, et al: Randomized controlled trial to evaluate laparoscopic surgery for colorectal cancer: Japan Clinical Oncology Group Study JCOG 0404. Jpn J Clin Oncol 2005; 35: 475-477
294） Schlachta CM, Mamazza J, Poulin EC. Are transverse colon cancers suitable for laparoscopic resection? Surg Endosc 2007; 21: 396-399
295） Senagore AJ, Delaney CP, Madboulay K, et al: Laparoscopic colectomy in obese and nonobese patients. J Gastrointest Surg 2003; 7: 558-561
296） Lascano CA, Kaidar-Person O, Szomstein S, et al: Challenges of laparoscopic colectomy in the obese patient: a review. Am J Surg 2006; 192: 357-365
297） Arteaga González I, Martín Malagón A, López-Tomassetti Fernández EM, et al: Impact of previous abdominal surgery on colorectal laparoscopy results: a comparative clinical study. Surg Laparosc Endosc Percutan Tech 2006; 16: 8-11
298） Kang SB, Park JW, Jeong SY, et al: Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy（COREAN trial）: short-term outcomes of an open-label randomised controlled trial. Lancet Oncol 2010; 11: 637-645
299） van der Pas MH, Haglind E, Cuesta MA, et al; COlorectal cancer Laparoscopic or Open Resection II（COLOR II）Study Group: Laparoscopic versus open surgery for rectal cancer（COLOR II）: short-term outcomes of a randomised, phase 3 trial. Lancet Oncol 2013; 14: 210-218
300） Yamamoto S, Yoshimura K, Konishi F, et al: Phase Ⅱ trial to evaluate laparoscopic surgery for stage 0/Ⅰ rectal carcinoma. Jpn J Clin Oncol 2008; 38: 497-500
301） National Comprehensive Cancer Network: NCCN clinical practice guideline in oncology. Rectal cancer-v. 1. 2008.
http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf（accessed 28 March 2008）
302） Stillwell AP, Buettner PG, Ho YH: Meta-analysis of survival of patients with stage Ⅳ colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg 2010; 34: 797-807
303） Cummins ER, Vick KD, Poole GV: Incurable colorectal carcinoma: The role of surgical palliation. Am Surgeon 2004; 70: 433-437
304） Seo GJ, Park JW, Yoo SB, et al: Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage Ⅳ colorectal cancer. J Surg Oncol 2010; 102: 94-99
305） Aslam MI, Kelkar A, Sharpe D, et al: Ten years experience of managing the primary tumours in patients with stage Ⅳ colorectal cancers. Int J Surg 2010; 8: 305-313
306） McCahill LE, Yothers G, Sharif S, et al: Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol 2012; 30: 3223-3228
307） Law WL, Chan WF, Lee YM, et al: Non-curative surgery for colorectal cancer: critical appraisal of outcomes. Int J Colorectal Dis 2004; 19: 197-202
308） Konyalian VR, Rosing DK, Haukoos JS, et al: The role of primary tumour resection in patients with stage Ⅳ colorectal cancer. Colorectal Dis 2007; 9: 430-437
309） Sarela AI, Guthrie JA, Seymour MT, et al: Non-operative management of the primary tumour in patients with incurable stage Ⅳ colorectal cancer. Br J Surg 2001; 88: 1352- 1356
310） Muratore A, Zorzi D, Bouzari H, et al: Asymptomatic colorectal cancer with un-resectable liver metastasis: Immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2006; 14: 766-770
311） Mentha G, Majno PE, Andres A, et al: Neoadjuvant chemotherapy and resection of advanced synchronous liver metastasis before treatment of the colorectal primary. Br J Surg 2006; 93: 872-878
312） Karoui M, Charachon A, Delbaldo C, et al: Stents for palliation of obstructive metastatic colon cancer. Impact on management and chemotherapy administration. Arch Surg 2007; 142: 619-623
313） Lee HJ, Hong SP, Cheon JH, et al: Long-term outcome of palliative therapy for malignant colorectal obstruction in patients with unresectable metastatic colorectal cancers: endoscopic stenting versus surgery. Gastrointest Endosc 2011; 73: 535-542
314） Lee WS, Baek JH, Kang JM, et al: The outcome after stent placement or surgery as the initial treatment for obstructive primary tumor in patients with stage Ⅳ colon cancer. Am J Surg 2012; 203: 715-719
315） Rosen SA, Buell JF, Yoshida A, et al: Initial presentation with stage Ⅳ colorectal cancer. How aggressive should we be? Arch Surg 2000; 135: 530-535
316） Pestieau SR, Sugarbaker PH: Treatment of primary colon cancer with peritoneal carcinomatosis comparison of concomitant vs. delayed management. Dis Colon Rectum 2000; 43: 1341-1348
317） Sugarbaker PH: Peritonectomy procedures. Ann Surg 1995; 221: 29-42
318） Verwaal VJ, Ruth S, Witkamp A, et al: Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12: 65-71
319） Yan TD, Black D, Savady R, et al: Systemic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006; 24: 4011-4019
320） Bijelic L, Yan TD, Sugarbaker PH: Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol 2007; 14: 2281-2288
321） Ambiru S, Miyazaki M, Ito H, et al: Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998; 82: 274-278
322） Shah SA, Haddad R, Al-Sukhni W, et al: Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 2006; 202: 468-475
323） 服部憲史，金光幸秀，小森康司，他: 大腸癌肝・肺転移切除例の検討―肺転移単独と肝肺2 臓器転移との比較―．癌の臨床2010; 56（11）: 789-796．
324） Adam R, de Haas RJ, Wicherts DA, et al: Concomitant extrahepatic disease in patients with colorectal liver metastases: when is there a place for surgery? Ann Surg 2011; 253: 349-359
325） Nagakura S, Shirai Y, Yamato Y, et al: Simultaneous detection of colorectal carcinoma liver and lung metastases does not warrant resection. J Am Coll Surg 2001; 193: 153-160
326） Mineo TC, Ambrogi V, Tonini G, et al: Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg 2003; 197: 386-391
327） Limmer S, Oevermann E, Killaitis C, et al: Sequential surgical resection of hepatic and pulmonary metastases from colorectal cancer. Langenbecks Arch Surg 2010; 395: 1129-1138
328） Brouquet A, Vauthey JN, Contreras CM, et al: Improved survival after resection of liver and lung colorectal metastases compared with liver-only metastases: a study of 112 patients with limited lung metastatic disease. J Am Coll Surg 2011; 213: 62-69
329） Lorenz M, Müller HH, Schramm H, et al: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases（Arbeitsgruppe Lebermetastasen）Ann Surg 1998; 228: 756-762
330） 森 武生，高橋慶一，大植雅之ほか: 大腸癌肝転移に対する肝切除後の残肝再発予防としての動注療法．消化器外科24: 313-319，2001
331） Kemeny MM, Adak S, Gray B, et al: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol 2002; 20: 1499-1505
332） Kanemitsu Y, Kato T, Shimizu Y, et al: Colorectal Cancer Study Group（CCSG）of Japan Clinical Oncology Group: A randomized phase Ⅱ/Ⅲ trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603. Jpn J Clin Oncol 2009; 39: 406-409
333） Delaunoit T, Alberts SR, Sargent DJ, et al: Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005; 16: 425-429
334） Folprecht G, Grothey A, Alberts S, et al: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-1319
335） Folprecht G, Gruenberger T, Bechstein WO, et al: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47
336） Okines A, Puerto OD, Cunningham D, et al: Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-Ⅲ NO16966 trial. Br J Cance 2009; 101: 1033-1038
337） Bismuth H, Adam R, Lévi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-520
338） Adam R, Delvart V, Pascal G, et al: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657
339） Nuzzo G, Giuliante F, Ardito F, et al: Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg 2007; 11: 318-324
340） Wanebo HJ, Koness RJ, Vezeridis MP, et al: Pelvic resection of recurrent rectal cancer. Ann Surg 1994; 220: 586-595; discussion 595-597
341） Ogunbiyi OA, McKenna K, Birnbaum EH, et al: Aggressive surgical management of recurrent rectal cancer―is it worthwhile? Dis Colon Rectum 1997; 40: 150-155
342） Kusters M, Dresen RC, Martijn H, et al: Radicality of resection and survival after multimodality treatment is influenced by subsite of locally recurrent rectal cancer. Int J Radiat Oncol Biol Phys 2009; 75: 1444-1449
343） Moriya Y, Akasu T, Fujita S, et al: Total pelvic exenteration with distal sacrectomy for fixed recurrent rectal cancer in the pelvis. Dis Colon Rectum 2004; 47: 2047-2053
344） Kido A, Koyama F, Akahane M, et al: Extent and contraindications for sacral amputation in patients with reccurent rectal cancer: a systematic literature review. J Orthop Sci 2011; 16: 286-290
345） Temple WJ, Saettler EB: Locally recurrent rectal cancer: role of composite resection of extensive pelvic tumors with strategies for minimizing risk of recurrence. J Surg Oncol 2000; 73: 47-58
346） Henry LR, Sigurdson E, Ross EA, et al: Resection of isolated pelvic recurrences after colorectal surgery: long-term results and predictors of improved clinical outcome. Ann Surg Oncol 2007; 14: 1081-1091
347） Rodriguez-Bigas MA, Herrera L, Petrelli NJ: Surgery for recurrent rectal adenocarcinoma in the presence of hydronephrosis. Am J Surg 1992; 164: 18-21
348） Larsen SG, Wiig JN, Giercksky KE: Hydronephrosis as a prognostic factor in pelvic recurrence from rectal and colon carcinomas. Am J Surg 2005; 190: 55-60
349） Kanemitsu Y, Hirai T, Komori K, et al: Prediction of residual disease or distant metastasis after resection of locally recurrent rectal cancer. Dis Colon Rectum 2010; 53: 779-789
350） Hartley JE, Lopez RA, Paty PB, et al: Resection of locally recurrent colorectal cancer in the presence of distant metastases: can it be justified? Ann Surg Oncol 2003; 10: 227-233
351） Vermaas M, Ferenschild FT, Nuyttens JJ, et al: Preoperative radiotherapy improves outcome in recurrent rectal cancer. Dis Colon Rectum 2005; 48: 918-928
352） Saito N, Koda K, Takiguchi N, et al: Curative surgery for local pelvic recurrence of rectal cancer. Dig Surg 2003; 20: 192-199
353） Lowy AM, Rich TA, Skibber JM, et al: Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma. Ann Surg 1996; 223: 177-185
354） Valentini V, Morganti AG, De Franco A, et al: Chemoradiation with or without intraoperative radiation therapy in patients with locally recurrent rectal carcinoma: prognostic factors and long term outcome. Cancer 1999; 86: 2612-24
355） Wiggers T, de Vries MR, Veeze-Kuypers B: Surgery for local recurrence of rectal carcinoma. DCR 1996 Surgery for local recurrence of rectal carcinoma. Dis Colon Rectum 1996; 39: 323-328
356） Haddock MG, Gunderson LL, Nelson H, et al: Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients. Int J Radiat Oncol Biol Phys 2001; 49: 1267-1274
357） Mohiuddin M, Marks G, Marks J: Long-term results of reirradiation for patients with recurrent rectal carcinoma. Cancer 2002; 95: 1144-1150
358） Shoup M, Guillem JG, Alektiar KM, et al: Predictors of survival in recurrent rectal cancer after resection and intraoperative radiotherapy. Dis Colon Rectum 2002; 45: 585-592
359） Adam R, Pascal G, Castaing D, et al: Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052-1061; discussion 1061-1064
360） Tanaka K, Adam R, Shimada H, et al: Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003; 90: 963-969
361） Nordlinger B, Sorbye H, Glimeliuset B, et al: Peri-operative FOLFOX4 chemotherapy and surgery for resectable liver metastases from colorectal cancer: Long-term survival results of the EORTC intergroup phase Ⅲ study 40983. ASCO 2012, Abstract #3508
362） Mulier S, Ruers T, Jamart J, et al: Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? An update. Dig Surg 2008; 25: 445-460
363） Berber E, Siperstein A: Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol 2008; 15: 2757-2764
364） Elias D, Baton O, Sideris L, et al: Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections. Ann Surg Oncol 2004; 11: 500-505
365） Berber E, Tsinberg M, Tellioglu G, et al: Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg 2008; 12: 1967-1972
366） Ruers T, Punt C, Van Coevorden F, et al: EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie（ALM-CAO）and the National Cancer Research Institute Colorectal Clinical Study Group（NCRI CCSG）: Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase Ⅱ study（EORTC 40004）. Ann Oncol 2012; 23: 2619-2626
367） Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-1097
368） Sundararajan V, Mitra N, Jacobson JS, et al: Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002; 136: 349-357
369） Jessup JM, Stewart A, Greene FL, et al: Adjuvant chemotherapy for stage Ⅲ colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005; 294: 2703-2711
370） Tournigand C, André T, Bonnetain F, et al: Adjuvant therapy with fluorouracil and oxaliplatin in stage Ⅱ and elderly patients（between ages 70 and 75 years）with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012; 30: 3353-3360
371） QUASAR Collaborative Group, Gray R, Barnwell J, et al: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-2029
372） Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials（IMPACT）investigators. Lancet 1995; 345: 939-944
373） Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage Ⅱ and Ⅲ colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797-1806
374） Figueredo A, Charette ML, Maroun J, et al: Adjuvant therapy for stage Ⅱ colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol 2004; 22: 3395-3407
375） Schrag D, Rifas-Shiman S, Saltz L, et al: Adjuvant chemotherapy use for Medicare beneficiaries with stage Ⅱ colon cancer. J Clin Oncol 2002; 20: 3999-4005
376） O ’Connell MJ, Lavery I, Yothers G, et al: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage Ⅱ/Ⅲ colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010; 28: 3937-3944
377） Salazar R, Roepman P, Capella G, et al: Gene expression signature to improve prognosis prediction of stage Ⅱ and Ⅲ colorectal cancer. J Clin Oncol 2011; 29: 17-24
378） Gray RG, Quirke P, Handley K, et al: Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage Ⅱ colon cancer. J Clin Oncol 2011; 29: 4611-4619
379） O ’Connell MJ, Laurie JA, Kahn M, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16: 295-300
380） Chau I, Norman AR, Cunningham D, et al: A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16: 549-557
381） Tamagawa H, Iwamoto S, Takahashi T, et al: FOLFIRI plus bevacizumab（bev）as secondline therapy in patients（pts）with metastatic colorectal cancer（mCRC）who have failed first-line bev plus oxaliplatin-based therapy: The randomized phase Ⅲ EAGLE study. Proc Am Soc Clin Oncol 2013; 32:（ Abstr 3516）
382） Grothey A, Sugrue MM, Purdie DM, et al: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study（BRiTE）. J Clin Oncol 2008; 26: 5326-5334
383） Kemeny NE, Niedzwiecki D, Hollis DR, et al: Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers（CALGB 9481）. J Clin Oncol 2006; 24: 1395-1403
384） Mocellin S, Pilati P, Lise M, et al: Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007; 25: 5649-5654
385） Kemeny N, Jarnagin W, Paty P, et al: PhaseⅠ trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23: 4888-4896
386） Arai Y, Ohtsu A, Sato Y, et al: Phase Ⅰ/Ⅱ study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI. J Vasc Interv Radiol 2012; 23: 1261-1267
387） Nishiofuku H, Tanaka T, Aramaki T, et al: Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. Clin Colorectal Cancer 2010; 9: 305-310
388） Sauer R, Liersch T, Merkel S, et al: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926-1933
389） Folkesson J, Birgisson H, Pahlman L, et al: Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23: 5644-5650
390） Nagawa H, Muto T, Sunouchi K, et al: Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy. Dis Colon Rectum 2001; 44: 1274-1280
391） Birgisson H, Påhlman L, Gunnarsson U, et al: Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 2005; 23: 6126-6131
392） Kim JS, Kim JS, Cho MJ, et al: Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002; 54: 403-408
393） Rodel C, Grabenbauer GG, Papadopoulos T, et al: Phase Ⅰ/Ⅱ trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104
394） Mohiuddin M, Winter K, Mitchell E, et al: Randomized phase Ⅱ study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006; 24: 650-655
395） Cancer and Leukemia Group B 89901, Ryan DP, Niedzwiecki D, et al: Phase Ⅰ/Ⅱ study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 2006; 24: 2557-2562
396） Sato T, Kokuba Y, Koizumi W, et al: PhaseⅠ trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007; 69: 1442-1447
397） Wong SJ, Winter K, Meropol NJ, et al: RTOG 0247: A randomized phase Ⅱ study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. Proc Am Soc Clin Oncol 2008; 26:（Abstr 4021）
398） Sato T, Ozawa H, Hatate K, et al: A Phase Ⅱ trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. Int J Radiat Oncol Biol Phys 2011; 79: 677- 683
399） Rades D, Kuhn H, Schultze J, et al: Prognostic factors affecting locally recurrent rectal cancer and clinical significance of hemoglobin. Int J Radiat Oncol Biol Phys 2008; 70: 1087-1093
400） Rödel C, Grabenbauer GG, Matzel KE, et al: Extensive surgery after high-dose preoperative chemoradiotherapy for locally advanced recurrent rectal cancer. Dis Colon Rectum 2000; 43: 312-319
401） Stocchi L, Nelson H, Sargent DJ, et al: Is en-bloc resection of locally recurrent rectal carcinoma involving the urinary tract indicated? Ann Surg Oncol 2006; 13: 740-744
402） De Paoli A, Chiara S, Luppi G, et al: Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase Ⅱ study. Ann Oncol 2006; 17: 246-251
403） Aschele C, Friso ML, Pucciarelli S, et al: A phase Ⅰ-Ⅱ study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 2005; 16: 1140-1146
404） Mehta VK, Cho C, Ford JM, et al: Phase Ⅱ trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 2003; 55: 132-137
405） Braendengen M, Tveit KM, Berglund A, et al: Randomized phase Ⅲ study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008; 26: 3687-3694
406） Gunderson LL, Nelson H, Martenson JA, et al: Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation＋/－5-FU. Int J Radiat Oncol Biol Phys 1997; 37: 601-614
407） Gunderson LL, Nelson H, Martenson JA, et al: Intraoperative electron and external beam irradiation with or without 5-fluorouracil and maximum surgical resection for previously unirradiated, locally recurrent colorectal cancer. Dis Colon Rectum 1996; 39: 1379-1395
408） Dresen RC, Gosens MJ, Martijn H, et al: Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer. Ann Surg Oncol 2008; 15: 1937-1947
409） Das P, Delclos ME, Skibber JM, et al: Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys 2010; 77: 60-65
410） Sun DS, Zhang JD, Li L, et al: Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer. Br J Radiol 2012; 85: 259-264
411） Freedman GM, Meropol NJ, Sigurdson ER, et al: PhaseⅠ trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007; 67: 1389-1393
412） Okada T, Kamada T, Tsujii H. et al: Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science（NIRS）. J Radiat Res 2010; 51: 355-364
413） Ohlsson B, Breland U, Ekberg H, et al: Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum 1995; 38: 619-626
414） Mäkelä JT, Laitinen SO, Kairaluoma MI: Five-year follow-up after radical surgery for colorectal cancer. Arch Surg 1995; 130: 1062-1067
415） Kjeldsen BJ, Kronborg O, Fenger C, et al: A prospective randomized study of follow-up after radial surgery for colorectal cancer. Br J Surg 1997; 84: 666-669
416） Pietra N, Sarli L, Costi R, et al: Role of follow-up in management of local recurrences of colorectal cancer. A prospective, randomized study. Dis Colon Rectum 1998; 41: 1127-1133
417） Schoemaker D, Black R, Giles L, et al: Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology 1998; 114: 7-14
418） Secco GB, Fardelli R, Gianquinto D, et al: Efficacy and cost of risk-adopted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol 2002; 28: 418-423
419） Grossmann EM, Johnson FE, Virgo KS, et al: Follow-up of colorectal cancer patients after resection with curative intent―the GILDA trial. Surg Oncol 2004; 13: 119-124
420） Rodriguez-Moranta F, Salö J, Arcusa A, et al: Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol 2006; 24: 386-393
421） Wattchow DA, Weller DP, Esterman A, et al: General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. Br J Cancer 2006; 24: 1116-1121
422） National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology-rectal cancer（version 4. 2013）.
http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf: accessed April 7, 2013
423） Viehl CT, Ochsner A, von Holzon U, et al: Inadequate quality of surveillance after curative surgery for colon cancer. Ann Surg Oncol 2010; 17: 2663-2669
424） Brawarsky P, Neville BA, Fitzmaurice GM, et al: Surveillance after resection for colorectal cancer. Cancer 2013; 119: 1235-1242
425） 杉原健一，小林宏寿，望月英隆: 大腸癌術後サーベイランス．Modern Physician 2008; 28: 1022-1025
426） Mulder SA, Kranse R, Damhuis RA, et al: The incidence and risk factors of metachronous colorectal cancer: an indication for follow-up. Dis Colon Rectum 2012; 55: 522-531
427） Sakamoto T, Matsuda T, Nakajima T, et al: How often should we perform surveillance colonoscopy after surgery for colorectal cancer? Int J Colorectal Dis 2013; 28: 835-840
428） Gan S, Wilson K, Hollington P: Surveillance of patients following surgery with curative intent for colorectal cancer. World J Gastroenterol 2007; 13: 3816-3823
429） Arditi C, Gonvers JJ, Burnand B, et al: EPAGE II Study Group: Appropriateness of colonoscopy in Europe（EPAGE II）. Surveillance after polypectomy and after resection of colorectal cancer. Endoscopy 2009; 41: 209-217
430） 甲斐俊吉，小泉浩一，今里 真，他: 大腸癌切除後の異時性重複癌について―大腸と他臓器との重複癌の検討―．外科1995; 57: 1300-1305
431） 万井真理子，吉川宣輝，西庄 勇，他: 大腸重複癌の臨床病理学的検討．日本大腸肛門病会誌2000; 53: 540-546
432） 塩澤 学，土田知史，菅野伸洋，他: 大腸癌における多臓器重複癌の検討．日消外会誌2007; 40: 1557-1564
433） Tanaka H, Hiyama T, Hanai A, et al: Second primary cancers following colon and rectal cancer in Osaka, Japan. Jpn J Cancer Res 1991; 82: 1356-1365
434） 寺本龍生，渡邊昌彦，北島政樹: 大腸癌二次発癌のサーベイランスと対策．消化器癌1997; 7: 169-172
435） Tsukuma H, Fujimoto I, Hanai A, et al: Incidence of second primary cancers in Osaka residents, Japan, with special reference to cumulative and relative risks. Jpn J Cancer Res 1994; 85: 339-345
436） Ueno M, Muto T, Oya M, et al: Multiple primary cancer: an experience at the Cancer Institute Hospital with special reference to colorectal cancer. Int J Clin Oncol 2003; 8: 162-167
437） Noura S, Ohue M, Seki Y, et al: Second primary cancer in patients with colorectal cancer after a curative resection. Dig Surg 2009; 26: 400-405
438） Yamamoto S, Yoshimura K, Ri S, et al: The risk of multiple primary malignancies with colorectal carcinoma. Dis Colon Rectum 2006; 49: S30-S36
439） Hoar SK, Wilson J, Blot WJ, et al: Second cancer following cancer of the digestive system in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985; 68: 49-82
440） McCredie M, Macfarlane GJ, Bell J, et al: Second primary cancers after cancers of the colon and rectum in New South Wales, Australia, 1972-1991. Cancer Epidemiol Biomarkers Prev 1997; 6: 155-160
441） Armed F, Goodman MT, Kosary C, et al: Excess risk of subsequent primary cancers among colorectal carcinoma survivors, 1975-2001. Cancer 2006; 107: 1162-1171
442） Lynge E, Jensen OM, Carstensen B: Second cancer following cancer of the digestive system in Denmark, 1943-80. Natl Cancer Inst Monogr 1985; 68: 277-308
443） Buiatti E, Crocetti E, Acciai A, et al: Incidence of second primary cancers in three Italian population-based cancer registries. Eur J Cancer 1997; 33: 1829-1834
444） Evans HS, Møller H, Robinson D, et al: The risk of subsequent primary cancers after colorectal cancer in southeast England. Gut 2002; 50: 647-652
445） 島谷英彦，藤井久男，小山文一，他: 大腸他臓器重複癌症例の検討．日本大腸肛門病会誌2003; 56: 294-298